Stevanato Group kept reporting healthy headlines, with Q4 and Q1 updates pointing to solid revenue growth, stronger high-value solutions and reaffirmed guidance. Holding Stevanato Group over the past year would have meant a 42.8% loss, including dividends. If you had bought in believing GLP-1 demand and U.S. onshoring would protect you, how did that outcome square with what was already visible in margins, customer mix, and regulatory risk before November 2025?
Stevanato Group has already moved. Pinpoint other ways to investigate the theme among 34 healthcare AI stocks .
The Two Stevanato Group Stories Investors Had To Weigh
The shares cost US$24.68 at the start of the period, and anyone looking at Stevanato Group then had to choose between two very different but reasonable stories.
The bullish view saw a Fair Value of US$28.35, which served as a rough guide to what the stock might be worth if rising biologics use and U.S. onshoring translated into higher demand for high value containment and better margins from sites like Fishers and Latina.
The cautious narrative pointed to a Fair Value of US$23 and focused on risks such as tighter rules on plastics and single use medical packaging raising compliance costs and forcing redesigns that could squeeze profitability.
What The Results Changed For The Stevanato Group Thesis
Stevanato Group's Q2 2026 report showed revenue at €302.003 million versus €280.037 million a year earlier, which supported the bullish demand story for high value solutions. Profit told a different story. Net income fell from €29.702 million to €22.958 million and net margin moved from 10.6% to 7.6%. The evidence cut both ways.
The hinge assumption here was that richer product mix and new plants would quickly improve profitability. When you test a similar claim elsewhere, track net income and net margin alongside sales to see whether scaling capacity is improving earnings quality or just adding volume.
What Stevanato Group's Lower Price Asks You To Believe
Today Stevanato Group trades at US$14.1, after a 42.8% loss over the past year. The selected Narrative places its Fair Value above that level and ties the gap to execution on higher margin products rather than a broad bet on GLP‑1 demand.
The argument leans on premium formats, site ramp and devices. A buyer now would be assuming Stevanato Group can turn Fishers and Latina into sustainably higher margin hubs that lift earnings quality.
"The main factor that needs to go right is the successful ramp and margin improvement of the Fishers and Latina facilities, including cartridge and syringe capacity, so that higher value products translate into the earnings and cash generation the company is targeting."
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all
Find Your Own Contrarian Opportunity
This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.
-
Company 1 - 23% below our estimate - supplies test gear and diagnostics utilities need as grids digitalize and electrification lifts load.
-
Company 2 - 35% below our estimate - expands device recommerce as subsidies and eco-policies nudge consumers toward trade ins and refurbishment.
-
Company 3 - 28% below our estimate - reshapes its deposit base and branch footprint after bolt on banking deals and digital upgrades.
Three companies from the same screener. Open every one of the 35 undervalued companies on it →
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include STVN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
